Francisco Partners Iv, L.P. Sells 1,296,177 Shares of GoodRx (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $3.50, for a total value of $4,536,619.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The shares were sold at an average price of $3.44, for a total value of $437,819.12.
• On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The stock was sold at an average price of $3.46, for a total transaction of $496,835.24.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total transaction of $1,666,071.75.

GoodRx Price Performance

GoodRx stock traded up $0.18 during midday trading on Wednesday, reaching $3.65. 3,534,816 shares of the stock were exchanged, compared to its average volume of 1,909,305. The company’s fifty day moving average is $3.18 and its 200-day moving average is $2.66. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a market cap of $1.25 billion, a PE ratio of 91.27, a PEG ratio of 1.73 and a beta of 1.60. GoodRx Holdings, Inc. has a 52 week low of $1.77 and a 52 week high of $5.81.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. The business had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.09 EPS. On average, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Analyst Ratings Changes

Several research firms recently commented on GDRX. The Goldman Sachs Group restated a “neutral” rating and set a $4.00 target price on shares of GoodRx in a research report on Friday, August 7th. Citigroup raised their price target on GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 7th. Wells Fargo & Company boosted their price objective on GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Barclays raised their target price on shares of GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research note on Thursday, August 20th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, GoodRx currently has a consensus rating of “Hold” and a consensus price target of $4.23.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in GDRX. Lazard Asset Management LLC raised its stake in GoodRx by 43.6% during the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock valued at $85,000 after buying an additional 5,201 shares during the last quarter. Brevan Howard Capital Management LP grew its stake in shares of GoodRx by 7.7% in the third quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock worth $404,000 after acquiring an additional 6,842 shares during the last quarter. Hirtle Callaghan & Co LLC grew its stake in shares of GoodRx by 60.3% in the fourth quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock worth $49,000 after acquiring an additional 6,869 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after acquiring an additional 7,580 shares in the last quarter. Finally, Quarry LP bought a new position in shares of GoodRx during the third quarter valued at $33,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.